Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fengye Kedianping mixture is a Traditional Chinese Medicine (TCM) liquid formulation developed by Shanghai Yuzhihua Pharmaceutical Technology Development for the treatment of acute bronchitis. It is specifically indicated for patients presenting with 'wind-heat cough' (wind-heat attacking the lung syndrome), a TCM diagnostic category characterized by symptoms such as cough, yellow phlegm, and fever. The drug is formulated as an oral mixture (heji) and has been evaluated in Phase 2 clinical trials in China (CTR20132374) to determine its safety, optimal dosage, and preliminary efficacy compared to placebo in adult populations. As a botanical product, it likely utilizes a multi-component approach to clear heat, resolve phlegm, and suppress cough, consistent with traditional therapeutic principles.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fengye Kedianping mixture.